CAREGENEX
LIVE

Serial Number

98354567

Owner

Access Bio, Inc.

Attorney

Rosaleen H. Chou

Filing Date

Jan 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CAREGENEX Trademark

Serial Number: 98354567

CAREGENEX is a trademark filed by Access Bio, Inc. on January 12, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Access Bio, Inc. (10 trademarks)

2033 Route 130 Unit H
Monmouth Junction, NJ 08852

Entity Type: 03

Trademark Details

Filing Date

January 12, 2024

Registration Date

Not Registered

Published for Opposition

March 25, 2025

Goods & Services

Diagnostic reagents for medical use; Medical diagnostic reagents and assays for diagnostic testing of medical samples for microorganisms, pathogens, genotypes, and viruses; Reagents for medical diagnostic use used in gene analysis and sequencing as well as DNA and RNA analysis and sequencing, namely, polymerase chain reaction (PCR) master mixes, polymerase chain reaction (PCR) reagents and enzymes, polymerase chain reaction (PCR) test kits containing DNA primers and template control DNA for polymerase chain reaction (PCR), all for medical diagnostic use; Diagnostic biomarker reagents for medical purposes; Reagents for medical diagnostic use used in the collection, storage and preparation of materials for gene analysis and sequencing as well as DNA and RNA analysis and sequencing, and in DNA extraction systems for crude lysates, DNA purification systems and cell filtration systems, diagnostic biomarker reagents for medical purposes, diagnostic reagents for medical use, medical diagnostic reagents for the analysis of body fluids, and medical diagnostic reagents and assays for testing body fluids for microorganisms; Reagents for medical diagnostic use used in detecting pathogens and genetic mutations, namely, testing kits for medical diagnostic use containing one or more of polymerase chain reaction (PCR) reagents, polymerase chain reaction (PCR) primers, cell culture medias, and diagnostic reagents and assays for diagnostic testing of medical samples for microorganisms, pathogens, genotypes, and viruses; Diagnostic reagents and consumables, namely, polymerase chain reaction (PCR) master mixes, polymerase chain reaction (PCR) reagents and enzymes, polymerase chain reaction (PCR) test kits containing DNA primers and template control DNA for polymerase chain reaction (PCR), for medical diagnostic use used in connection with polymerase chain reaction (PCR), molecular diagnostics, and gene analysis; Chemical preparations in the nature of medical diagnostic reagents for testing nucleic acid analysis, for medical use; Medical diagnostic reagents, assays, chemical reagents and kits consisting primarily of medical diagnostic reagents, assays, chemical reagents for medical testing and diagnostic purposes; Medical diagnostic reagents, and kits comprised of medical diagnostic reagents, collection tubes, buffers, tube holders, transport bags, and instruction sheets, for diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Diagnostic testing kits and assays for use in medical, clinic, and companion diagnostic testing in the fields of medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases

Research and development in the fields of biologics and biotechnology; Medical research laboratories; Biological research and analysis; Biochemical research and analysis; Biological, chemical, biochemical, bacteriological, DNA, RNA, protein, polynucleic acid and molecular analysis for scientific or research purposes

Medical analysis services for diagnostic and treatment purposes provided by medical laboratories

Reagents for scientific and research use; Reagents for use in gene analysis and sequencing; Reagents for use in DNA and RNA analysis and sequencing; Reagents for in vitro use in biochemistry and cell culture reagents for scientific and research use; Reagents for scientific and research use in the fields of gene analysis and sequencing, DNA analysis and sequencing, and RNA analysis and sequencing; Reagents for use in gene analysis and sequencing as well as DNA and RNA analysis and sequencing, namely, polymerase chain reaction (PCR) master mixes, polymerase chain reaction (PCR) reagents and enzymes, polymerase chain reaction (PCR) test kits containing DNA primers and template control DNA for polymerase chain reaction (PCR), all for scientific and research use; Biochemical reagents used for non-medical purposes; Diagnostic tests and testing kits primarily composed of reagents for scientific and research use purposes; Biological agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations used for non-medical purposes; Testing kits comprised primarily of reagents and assays for scientific or research use in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases

Apparatus and instruments for testing, analysis and diagnosis of samples, namely, medical diagnostic apparatus for testing DNA and RNA samples; DNA amplification apparatus, namely, thermocyclers for DNA and RNA testing for medical purposes; Medical apparatus for use in extracting DNA and RNA; Sample preparation device for medical diagnostic use; Medical apparatus for conducting polymerase chain reactions; Medical apparatus for conducting quantitative or real-time polymerase chain reactions; Quantitative PCR machines for conducting quantitative or real-time polymerase chain reactions; Medical equipment, namely, sample containers in the nature of containers for medical waste, rigid and semi-rigid containers for concentrates and solutions in solid or liquid form for medical use, blood containers for medical purposes sold empty, medical sample vials, dropping pipettes and magnetic stirrers used in the preparation of samples for testing; Kits comprising of medical sample vials, reagents and instructions for the preparation of samples for polymerase chain reaction (PCR) testing for medical purposes; Medical equipment, namely, racks for holding samples and vials during testing; Replacement and structural parts, fittings and accessories in the nature of capillary reagent tubes for medical use, medical sample tubes and vials for all the aforesaid goods

Research laboratory instrument for extracting and purifying DNA and RNA from samples; DNA amplification apparatus, namely, thermocyclers for scientific or medical research use; Downloadable software for use with thermocyclers and DNA amplification devices for use in conducting analysis of real-time polymerase chain reaction (PCR) data; Downloadable software for use in DNA and RNA analysis and sequencing, detection of genetic mutations, and detection of pathogens; Laboratory devices for detecting genetic sequences; Diagnostic apparatus for the detection of pathogens, not for medical purposes; Downloadable and recorded computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; Computer hardware and downloadable and recorded computer software for use in data analysis in the fields of medical, clinical, and companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2026 EXRA
SOU EXTENSION 2 GRANTED
May 15, 2026 EX2G
SOU EXTENSION 2 FILED
May 15, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
May 15, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 11, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 11, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 20, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 4, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 21, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 21, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 21, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 21, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 5, 2024 NWOS
NEW APPLICATION ENTERED
Jan 12, 2024 NWAP